COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC:

Get the latest research information from NIH: Menu

Pharmacokinetics, Safety and Tolerability of Fevipiprant Delivered Via a Once Daily Chewable Tablet in Children Aged 6 to < 12 Years With Asthma

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT03650400
Recruitment Status : Terminated (Company Decision)
First Posted : August 28, 2018
Last Update Posted : May 8, 2020
Information provided by (Responsible Party):
Novartis ( Novartis Pharmaceuticals )

No Study Results Posted on for this Study
Recruitment Status : Terminated
Actual Primary Completion Date : December 16, 2019
Actual Study Completion Date : January 22, 2020